Poop pills plus chemo: new combo tackles tough colon cancer
NCT ID NCT06801665
First seen Nov 01, 2025 · Last updated Jun 24, 2026 · Updated 36 times
Summary
This phase 2 trial tests whether transplanting healthy gut bacteria (fecal microbiota transplant) can boost the effects of immunotherapy and chemotherapy in 30 people with advanced colon cancer that has spread to the liver. Participants receive the combination for six cycles, then may continue with maintenance therapy. The main goal is to see how many patients' tumors shrink significantly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLON CANCER LIVER METASTASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Second People's Hospital of Changzhou
RECRUITINGChangzhou, China
Contact Phone: •••-•••-••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Fecal microbiota transplant (FMT) plus QL1706 (an immunotherapy), bevacizumab, and XELOX chemotherapy
What this could lead to
If it works, this could improve tumor shrinkage and delay cancer progression in people with advanced colon cancer that has spread to the liver.
What could go wrong
This is a small, early-phase trial with only 30 participants and no comparison group, so results may not apply broadly. Combining multiple treatments also raises the risk of serious side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.